Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Grants Priority Review for KALYDECO™ (ivacaftor), the First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis
FDA Grants Priority Review for KALYDECO™ (ivacaftor), the First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis
FDA Grants Priority Review for KALYDECO™ (ivacaftor), the First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis
Submitted by
admin
on December 15, 2011 - 11:02am
Source:
Yahoo
News Tags:
FDA
Kalydeco
Vertex
VX-770
cystic fibrosis
Headline:
FDA Grants Priority Review for KALYDECO™ (ivacaftor), the First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis
Do Not Allow Advertisers to Use My Personal information
